Lions Bay Mining Corp.

• Lions Bay Mining: Übernahmeziel BioVaxys kündigt Studie zu SARS-CoV-2-Impfstoff und finale Vereinbarung an

  Lions Bay freut sich bekannt zu geben, dass sich die Firma BioVaxys LLC nach eigenen Angaben derzeit auf eine präklinische Studie zu seinem geschützten Impfstoff gegen SARS-CoV-2, den Erreger der Covid-19-Erkrankung, vorbereitet. Wie Lions Bay vor Kurzem mitteilte, hat das Unternehmen eine unverbindliche Absichtserklärung datiert mit 17.4.2020 zur Übernahme der Firma BioVaxys unterzeichnet. BioVaxys ist ein privat [...]

  weiterlesen

  22.05.2020

  von IRW-Press
• Lions Bay Mining Corp. übernimmt BioVaxys LLC

  Lions Bay Mining Corp. kündigte gestern an, dass es eine nicht bindende Absichtserklärung mit BioVaxys LLC geschlossen hat, in deren Rahmen Lions Bay das Unternehmen erwerben wird. Dabei soll BioVaxys unternehmenseigene Tochtergesellschaft von Lions Bay werden. Die Absichtserklärung unterliegt verschiedener Regulierungen und Bedingungen, und zur Erfüllung muss es innerhalb von 40 Tagen zu einer definitiven [...]

  weiterlesen

  21.04.2020

  von Redaktion

weitere Meldungen

• BioVaxys Technology Corp. Announces Interim Results from Preclincal Study of Its SARS-CoV-2 Vaccine

  BioVaxys Technology is pleased to announce that interim results from its ongoing preclinical animal study of BXV-0320, its SARS-CoV-2 vaccine candidate, show a good emerging tolerability profile with no observed side effects or noteworthy clinical observations. Five weeks post-administration of BVX-0320 in the murine animal model, no toxicities have been observed, nor any injection site reactions. Dr. David Berd [...]

  weiterlesen

  14.10.2020

  von Newsfile
• BioVaxys Technology Corp: Closing of Acquisition of BioVaxys Inc.

  BioVaxys Technology Corp. is pleased to announce the completion of its formerly announced acquisition of all of the securities BioVaxys Inc. The Transaction was determined to be a "fundamental change" pursuant to the policies of the Canadian Securities Exchange and the Company has re-classified itself from being a resource issuer to an industrial issuer operating in the life sciences industry. Pursuant to the [...]

  weiterlesen

  06.10.2020

  von Newsfile
• Lions Bay Mining Corp. Announces Closing of Final Tranche of Non-Brokered Private Placement

  Lions Bay Mining is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement. Under the final tranche of the Private Placement, the Company issued 2,954,582 units at a price of $0.22 per Unit for total gross proceeds of approximately $650,008.00, and together with the first tranche which completed on August 26, 2020, raised total aggregate gross [...]

  weiterlesen

  04.09.2020

  von Newsfile
• Lions Bay Mining Announces Execution of Secured Lending Facility with BioVaxys Inc. and Production of Vaccine Candidate for Preclinical Study

  Lions Bay Mining Corp. is pleased to announce that, following the execution of a Share Exchange Agreement with BioVaxys, the Company has executed a USD$180,000 secured lending facility with BioVaxys, the proceeds of which will be used primarily for BioVaxys' preclinical studies of BVX-0320, a novel vaccine candidate for prevention of Covid-19. BioVaxys has contracted for the production of it's BVX-0320 Vaccine [...]

  weiterlesen

  23.06.2020

  von Newsfile
• Lions Bay Mining Corp. Announces Definitive Agreement for BioVaxys Acquisition and Concurrent Financing

  Lions Bay Mining is pleased to announce that it has executed a Share Exchange Agreement with BioVaxys Inc., a clinical-stage immunotherapeutics company developing vaccine platforms for SARS-CoV-2 and various cancers. Under the terms of transaction, the Company will acquire all of the issued and outstanding shares of common stock of BioVaxys. Terms of the Proposed Transaction Pursuant to the Proposed Transaction, the [...]

  weiterlesen

  04.06.2020

  von Newsfile

weitere engl. Meldungen